Treatment related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood (UCB) transplantation, including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation (TBI), fludarabine, and cyclophosphamide regimen. In an attempt to reduce regimen-related toxicity, we previously studied a modified myeloablative regimen with total body irradiation (1350 cGy) and fludarabine (160 mg/m2); TRM was decreased but neutrophil engraftment was suboptimal. Therefore, in order to improve engraftment while still minimizing regimen-related toxicity, we piloted a myeloablative regimen with the addition of thiotepa (10 mg/kg) to TBI and fludarabine conditioning. Thirty-one adult patients (median age 46 years; range, 19–65) with hematologic malignancies (acute leukemia/MDS 77%, lymphoid malignancy 23%) underwent single (n=1) or double (n=30) UCB transplantation from 2010 to 2015 at our institution. The cumulative incidence (CI) of neutrophil engraftment was 90% (95% CI, 70–97%) by 60 days, with a median time to engraftment of 21 days (95% CI, 19–26 days). The CI of platelet engraftment was 77% (95% CI, 57–89%) by 100 days, with a median time to engraftment of 47 days (95% CI, 37–73 days). Cumulative incidences of grades II–IV and grades III–IV acute GVHD at day 100 were 45% (95% CI, 27–62%) and 10% (95% CI, 2–23%), respectively. The overall incidence of chronic GVHD at 2 years was 40% (95% CI, 22–57%), with 17% (95% CI, 6–33%) of patients experiencing moderate to severe chronic GVHD by 2 years. Treatment-related mortality at 180 days was 13% (95% CI, 4–27%), while at 1 year was 24% (95% CI, 10–41%) and at 3 years was 30% (95% CI, 13–49%). Relapse at 1 year was 13% (95% CI, 4–27%) and at 3 years was 19% (95% CI, 6–38%). With a median follow-up of 35.5 months (95% CI, 12.7–52.2 months), disease-free and overall survival at 3 years was 51% (95% CI, 29–69%) and 57% (95% CI, 36–73%), respectively. This regimen represents a reasonable alternative to myeloablative conditioning with TBI, fludarabine, and cyclophosphamide and warrants further study.